CORDIS - EU research results
CORDIS

Development and Commercialisation of Transbronchial Lung Ablation to Treat Lung Cancer

Project description

A minimally invasive treatment for lung cancer

Lung cancer is the most common cause of cancer-related deaths in Europe, with a dismal five-year survival rate. Although surgical resection of the tumour prolongs survival, only a small proportion of patients are fit to undergo surgery. Scientists of the EU-funded TABLA project have developed a pioneering, minimally invasive device that can destroy the targeted tumour. It employs a catheter system that delivers microwave heating directly to cancer cells. The procedure can be performed in an outpatient setting, improving patient outcomes and reducing healthcare costs. The project will conduct clinical trials to validate the efficacy of the device and undertake the necessary optimisation steps towards device commercialisation.

Objective

Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed
each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds.
The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in
economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery
due to co-morbidities.

Endowave have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive
intervention. The patented technology uses a flexible catheter system, that can be navigated through the patient’s airway to
deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be
delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system.

The global market opportunity for lung cancer exceeds €3.6 billion. Endowave has formed a consortium of leading
companies that seeks to commercial Endowave’s technology and capture this market opportunity. The proposal is seeking
funding to complete the final development of the microwave system, carry out clinical studies achieve regulatory approval.
This will enable Endowave to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative
market penetration forecasts. This project will drive job generation in Endowave and consortium partners as sales volumes
increase.

Coordinator

ENDOWAVE LIMITED
Net EU contribution
€ 2 033 552,62
Address
88 HARCOURT STREET
D02D K18 Dublin
Ireland

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ireland Eastern and Midland Dublin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 2 905 076,25

Participants (4)